Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3/A - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
3 - YD Bio Ltd (0002011674) (Issuer)
Fastest customizable press release news feed in the world
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. ("YD Bio USA") entered into a Master Strategic Alliance Agreement (the "Agreement") with YC Biotech Co., Ltd. ("YC Biotech") on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the "FDA") for YC Biotech's Contract Research
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it has entered into a binding Letter of Intent (the "LoI") to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a Taiwan-based dendritic cell immunotherapy platform. The LoI, executed on January 20, 2026, signifies a definitive step towards integrating SSMC's advanced immunocell therapy capabilities into YD Bio Ltd's strategic portfolio, further solidifying the Company's strategic transformation from
Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the "MOU") to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery. The MOU is non-binding and there ca
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a focused, catalyst-driven strategy for 2026, and plans to transition from platform validation to accelerated asset-level clinical and commercial development, subject to regulatory feedbac
Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics. The California operations center is currently in the site evaluation phase and the specific host city has not yet been finalized. It will support clinical collaboration, regulatory strategy and scaled operational capabil
Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer detection powered by DNA methylation and multi-biomarkers, next-generation precision diagnostics and stem cell therapy & exosome platforms focused on ophthalmology conditions. With 1,500+ visitors and 5
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection. Building on the Company's previously announced support for the research‑use‑only OkaiDx breast cancer monitoring assay ava
Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a set of regulatory and clinical milestones that together mark its first commercial entry into U.S. eye care and limbal stem cells ("LSC") exosome‑based therapeutics. Through its partner 3D Global Biotech Inc. ("3D Global Biotech"), Exovisse Contact Lenses have obtained FDA 510(k) clearance as a Class II medical device, enabling legal marketing in the United States. In parallel, its Exovisse Artificial Tears have been develop
424B3 - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
424B3 - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
S-8 - YD Bio Ltd (0002011674) (Filer)
424B3 - YD Bio Ltd (0002011674) (Filer)